



Published in final edited form as:

Lung. 2018 February ; 196(1): 49–57. doi:10.1007/s00408-017-0080-8.

HIV infection, pulmonary tuberculosis and COPD in rural Uganda: A cross-sectional study

Crystal M. North, MD^{1,3}, Joseph G. Allen³, Samson Okello⁴, Ruth Sentongo⁴, Bernard Kakuhikire⁴, Edward T. Ryan^{2,5,6}, Alexander C. Tsai^{2,7}, David C. Christiani^{1,3}, and Mark J. Siedner^{2,4,5}

¹Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital ²Harvard Medical School ³Department of Environmental Health, Harvard T.H. Chan School of Public Health ⁴Mbarara University of Science and Technology, Mbarara, Uganda ⁵Division of Infectious Diseases, Massachusetts General Hospital ⁶Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health ⁷Chester M. Pierce, MD Division of Global Psychiatry, Massachusetts General Hospital

Abstract

Purpose: HIV is associated with chronic obstructive pulmonary disease (COPD) in high resource settings. Similar relationships are less understood in low resource settings. We aimed to estimate the association between HIV infection, tuberculosis and COPD in rural Uganda.

Methods: The Uganda Non-Communicable Diseases and Aging Cohort study observes people 40 years and older living with HIV (PLWH) on antiretroviral therapy, and population-based HIV-uninfected controls in rural Uganda. Participants completed respiratory questionnaires and post-bronchodilator spirometry.

Results: Among 269 participants with spirometry, median age was 52 (IQR 48–55), 48% (n=130) were ever-smokers, and few (3%, n=9) reported a history of COPD or asthma. All participants with prior tuberculosis (7%, n=18) were PLWH. Among 143 (53%) PLWH, median CD4 count was 477 cells/mm³ and 131 (92%) were virologically suppressed. FEV1 was lower among older individuals (–0.5 %pred/year, 95% CI 0.2–0.8, p<0.01) and those with a history of tuberculosis (–14.4 %pred, 95% CI –23.5 – –5.3, p<0.01). COPD was diagnosed in 9 (4%) participants, eight of whom (89%) were PLWH, 6 of whom (67%) had a history of tuberculosis, and all of whom (100%) were men. Among 287 participants with complete symptom questionnaires, respiratory symptoms were more likely among women (AOR 3.9, 95% CI 2.0–7.7, p<0.001) and those in homes cooking with charcoal (AOR 3.2, 95% CI 1.4–7.4, p=0.008).

Corresponding Author: Crystal M. North, MD, Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, 55 Fruit Street, BUL-148, Boston, MA 02114, cnorth@mgh.harvard.edu.

Conflicts of Interest: None

Ethical Approval: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional an/or national research committee and with the 1964 Helsinki declaration and its later amendemnts or comparable ethical standards.

Conclusion: In rural Uganda, COPD may be more prevalent among PLWH, men, and those with prior tuberculosis. Future research is needed to confirm these findings and evaluate their broader impacts on health.

Keywords

Spirometry; Africa; lung function; AIDS; tuberculosis

INTRODUCTION

Chronic obstructive pulmonary disease (COPD) affects over 200 million people and is the third leading cause of death globally[1]. An estimated 90% of COPD-related deaths occur in low and middle-income countries (LMIC)[2], where COPD epidemiology is incompletely understood. For instance, although tobacco is the primary cause of COPD in much of the world, the estimated fraction of tobacco-associated COPD mortality in LMICs is only 12% in women and 45% in men[3]. In sub-Saharan Africa (SSA), air pollution, recurrent pulmonary infections and malnutrition additionally coalesce to increase the COPD burden[4].

HIV infection increases COPD risk. Compared to HIV-uninfected individuals, COPD is more prevalent, presents earlier, and progresses more rapidly among PLWH[5–8]. Though data are conflicting on associations with antiretroviral therapy [5,9], virologic failure and lower CD4 T cell counts are associated with increased odds of COPD[10,11]. Tuberculosis, a well-documented risk among PLWH, also increases risk for subsequent COPD[12]. Data on the relationships between HIV, tuberculosis and COPD in SSA are sparse. Since SSA is home to over 75% of the global population of PLWH, the magnitude of undiagnosed COPD may significantly impact regional morbidity and mortality. To address this gap in knowledge, we measured associations between chronic HIV infection, prior tuberculosis, and lung function within a mixed cohort of PLWH and population-based, HIV-uninfected controls in rural Uganda.

STUDY POPULATION AND METHODS

The Uganda Non-Communicable Diseases and Aging Cohort (UGANDAC, NCT02445079) is an observational cohort study of PLWH and population-based controls. PLWH were recruited from Mbarara Regional Referral Hospital's HIV clinic using convenience sampling, provided they were at least 40 years of age and on antiretroviral therapy (ART) for at least three years. There were no exclusion criteria. The HIV-uninfected population was recruited from a parish about 20 kilometers from the clinic, using census data to recruit people matched by age (quartile) and sex to the PLWH cohort. HIV serostatus was confirmed prior to yearly study visits for the HIV-uninfected population. Yearly study visits gathered data on demographics, medical history, respiratory symptoms[13], socioeconomic status[14], smoking history[15] and cooking practices. ART regimens, HIV viral load and CD4+ T cell counts within one year of pulmonary function testing were obtained through clinical record abstraction for PLWH. We defined virologic suppression as a viral load below the limit of assay detection (plasma specimens: <40 copies/ μ L; dried blood spots: <550

copies/ μL ; Cobas[®] assays, Roche Molecular Systems Inc; detection limit changed due to change in clinic protocol during study enrollment period).

Participants were defined as having respiratory symptoms if they reported any of the following: cough, phlegm production, dyspnea or wheezing. Chronic cough was defined as a cough on most days for at least three months, chronic bronchitis was defined as a chronic cough for at least two consecutive years, dyspnea was defined as shortness of breath when hurrying on flat ground or walking up a slight hill, and wheezing was defined as ever having a ‘wheezy or whistling’ chest. Dyspnea severity was categorized from mild (needing to walk more slowly than other people of a similar age due to breathlessness) to severe (too breathless to leave the house or breathlessness on dressing or undressing).

Our primary outcome of interest was pulmonary function (forced expiratory volume in one second (FEV1), forced vital capacity (FVC)). Study staff performed pre-bronchodilator spirometry with EasyOne[®] Plus spirometers (nDD Medical Technologies; Andover, MA) on all study participants, and post-bronchodilator spirometry on those meeting criteria for obstruction (defined below), in accordance with American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines[16]. Spirometers were factory-calibrated prior to use, and calibration was confirmed each morning using a 3-liter syringe (nDD Medical Technologies, Andover, MA). Spirometry was interpreted using National Health and Nutrition Examination Survey III (NHANES III) prediction equations and African American correction factors[17], based on similarities with East African prediction equations[18]. ATS/ERS guidelines were used to define acceptability and reproducibility[19]. Tests with only two acceptable trials were included if the best values were within 200mL of one another. Participants with FEV1:FVC<0.7 received 4 puffs of albuterol (Ventolin, GlaxoSmithKline, Philadelphia PA) and spirometry was repeated after 10 minutes. We defined COPD as a post-bronchodilator FEV1:FVC<0.7 and graded severity according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria[20].

Study procedures were approved by the Partners Healthcare and Mbarara University of Science and Technology human studies ethics committees, and all participants gave written informed consent.

Statistical Analysis

We compared participant characteristics by HIV serostatus using Student’s t tests, Wilcoxon rank sum testing, χ squared or Fisher’s exact testing. To assess for selection bias, we compared characteristics between study participants who completed and declined spirometry, and those with and without ATS/ERS-acceptable results. We identified predictors of impaired FEV1 using a modified forward selection process by fitting multivariable linear regression models that included HIV, tuberculosis, and other covariates with a p-value < 0.2 in unadjusted analyses. We identified predictors of respiratory symptoms using logistic regression equations that included smoking status and other covariates with a p-value < 0.2 in unadjusted analyses. Candidate covariates were selected based on scientific plausibility and included age, gender, smoking, prior tuberculosis, cooking fuel type, socioeconomic status (as measured by the asset ownership index[14]), education, occupation and body mass index (BMI). We compared COPD prevalence by

covariates of interest, and evaluated differences in lung function by CD4 count, viral load and ART duration among PLWH. Data were analyzed with Stata 13 (StataCorp, College Station, Texas).

RESULTS

All 287 study participants completed respiratory questionnaires and 269 (94%) also completed spirometry. Among those with spirometry, PLWH comprised 53% (n=143) of the cohort, 46% (n=125) were women, and the median age was 52 years (Table 1). Fewer PLWH were currently smoking compared to HIV-uninfected participants (9% vs. 22%, $p=0.01$). Participants were mostly farmers (67%, n=179) and generally had completed at most a primary school education (89%, n=239). All households used either firewood (86%, n=229) or charcoal (14%, n=38) for cooking. Few reported a history of COPD (1%, n=4) or asthma (2%, n=5); while 9% (n=23) had prior pneumonia and 7% (n=18) had prior tuberculosis. All participants with prior tuberculosis were PLWH, and 94% (n=17) were men ($p<0.001$).

Most PLWH were virologically suppressed at last measurement (92%, n=131), and most (82%, n=117) had a CD4 count >350 cells/mm³ (median 477, IQR 368–633) (Table 2). Median time on antiretroviral therapy was nine years [IQR 8–10]. First line, non-nucleoside reverse transcriptase inhibitor-based ART was the most common regimen (92%, n=131). The remaining 8% (n=12) were taking protease inhibitor-based regimens.

Respiratory Symptoms

Respiratory symptoms were reported by 72 (25%) study participants (Figure 1). Among those who reported any respiratory symptoms, 49 (68%) endorsed dyspnea on exertion. Of participants reporting dyspnea, most PLWH (70%, n=19) reported severe/very severe dyspnea and most HIV-uninfected participants (67%, n=14) reported mild/moderate dyspnea ($p=0.04$). Any history of wheezing was endorsed by 31 (43%) of the cohort. Chronic cough was prevalent among 7 (10%), and 6 (8%) met criteria for chronic bronchitis. All participants with chronic bronchitis were PLWH.

In multivariable logistic regression models adjusted for predicted confounders, the odds of any respiratory symptoms were higher among women (AOR 3.9, 95% CI 2.0–7.7, $p<0.001$), and those in households cooking with charcoal (AOR 3.2 (versus firewood), 95% CI 1.4–7.4, $p=0.008$). There were no associations between odds of respiratory symptoms and smoking history, prior tuberculosis or HIV (Table 3).

Pulmonary Function

Among the 269 study participants with spirometry, 89% (n=239) met ATS/ERS interpretation criteria. Only four of the 18 who declined spirometry were PLWH (22%) compared to 143 of the 269 (n=53%) who completed spirometry ($p=0.01$). Otherwise, demographic characteristics were similar in comparing those who completed or declined spirometry (eTable 1), and in comparing those who did or did not have interpretable spirometry (eTable 2).

Among those with ATS/ERS-acceptable spirometry, mean FEV1, FVC and FEV1:FVC percent predicted were 103(±18), 104(±16) and 98(±8) respectively, none of which differed by HIV serostatus. In multivariable regression models adjusted for predicted confounders, FEV1 %predicted was lower among older-age individuals (−0.5 %predicted per year, 95% CI 0.2–0.8, $p < 0.01$) and those with prior tuberculosis (−14.4 %predicted, 95% CI −23.5 to −5.3, $p < 0.01$). There was no association between FEV1 %predicted and HIV serostatus or smoking history. Among PLWH, FEV1 %predicted was lower among those with detectable viral loads (−26.7 %predicted, 95% CI −41.4 to −12.0, $p < 0.001$) and those with lower CD4 counts (<350 versus >500: −9 %predicted, 95% CI −17.8 to −0.1, $p < 0.05$) (Table 3).

COPD prevalence was 4% (n=9), and was six times as high among PLWH (6%, n=8) compared to HIV-uninfected participants (1%, n=1; $P=0.04$) (Table 4). Most obstruction was Stage I or II in severity (89%, n=8). Prevalence estimates were unchanged when defining COPD as FEV1:FVC < lower limit of normal. All participants with COPD were men, and 6 (67%) had a history of tuberculosis ($p < 0.001$). COPD prevalence did not differ by CD4 count, viral load or ART duration (Table 2).

DISCUSSION

In summary, we found that COPD prevalence was lower than expected in rural Uganda, but more common among men, PLWH, and those with a history of tuberculosis.

This is the first study in Uganda to investigate associations between HIV, tuberculosis and COPD, joining three other spirometry-based studies in SSA. Cameroon investigators measured lower COPD prevalence among PLWH (2.2%) but describe similar associations between HIV, tuberculosis and COPD[21]. Their lower prevalence may be explained by a comparatively younger population with a lower smoking prevalence. Conversely, Nigerian investigators measured 15.4% prevalence of COPD among PLWH in urban Nigeria, although no association was found between COPD and tuberculosis[22]. Importantly, viral control was less common in the Nigerian cohort. Finally, a population-based study in Malawi found no association between HIV and COPD[23]. Of note, these investigators included PLWH at various disease stages. In North American HIV cohorts, by comparison, COPD prevalence has been moderately higher, ranging from 9% to 27%[5,24], possibly related to the higher smoking prevalence among PLWH in North America. Associations between lung function, high viral load and low CD4 count are consistent with published literature [10,11].

Prior tuberculosis may be largely responsible for the observed associations between HIV and COPD in SSA. PLWH are more susceptible to mycobacterial infection, particularly in TB-endemic regions such as SSA[12]. Tuberculosis increases the risk of COPD through several mechanisms, including infection-related parenchymal scarring and chronic airways inflammation from latently-infected pulmonary macrophages[25–27]. HIV itself may also directly cause COPD through the consequences of HIV-infected pulmonary macrophages, which lead to alveolar inflammation, epithelial barrier dysfunction, altered pulmonary oxidant-antioxidant balance, increased cellular apoptosis and altered respiratory tract microbial colonization, all of which are implicated in COPD pathogenesis[28–31]. Indeed,

HIV-associated systemic biomarkers of inflammation and immune activation, which persist despite viral suppression, have been associated with pulmonary dysfunction[26,27]. Associations between tuberculosis and COPD among PLWH in North American cohorts have not been described, possibly related to lower tuberculosis prevalence. Discerning the relative contributions of tuberculosis-mediated structural lung damage and HIV-mediated chronic inflammation to COPD risk in SSA is an important area of future study.

The relationship between ART and COPD risk remains unclear. We did not find an association between lung function and ART duration, but our sample was limited to individuals on longer-term ART. Some investigators have described a potentially protective effect of ART therapy on odds of COPD[7,32], which may be from ART-related reduction in pulmonary HIV viral load and inflammation. In contrast, others have found increased COPD risk among PLWH on ART[9,33], hypothesized to be from either direct pulmonary-toxic effects of ART regimens or restoration of immune activity against latent pulmonary infections. Importantly, the above studies do not include data on ART duration. Of further interest, the START study of immediate versus delayed ART initiation in newly diagnosed PLWH followed for a median of two years showed that very early ART initiation (CD4 >500) had no effect on lung function trajectory[34]. Unfortunately, because late presentation to HIV care remains common in SSA[35], these findings might not be generalizable to the regional population. Larger, locally conducted longitudinal studies are necessary to help clarify these associations.

All participants with COPD were men. Tuberculosis is twice as likely in men versus women in SSA[36–38], and while the pathophysiology of this differential susceptibility has yet to be determined, candidate mechanisms include sex-hormone effects on the immune system and/or differences in genetic susceptibility to infection by intracellular organisms[39]. Almost all participants with prior tuberculosis in our cohort were also men, thus we cannot differentiate whether a difference in COPD prevalence observed in our study was due to sex, prior tuberculosis, or some interaction between them. Our findings stand in contrast to other studies from Uganda[40] and other SSA cohorts[41,42] that identify COPD risk among women, hypothesized to be related to higher biomass smoke exposure from gender-based meal preparation roles[43], although sex-based differences in genetic susceptibility to inhaled toxins may also contribute[44–46].

Finally, we did not find an association between smoking history and respiratory symptoms or lung function. This may be related to misclassification bias introduced by self-report, which has been previously reported in this study population[47]. Alternatively, smoking quantity is lower in resource-limited settings[48]. In this cohort, 83% smoked less than 10 pack-years, with no difference by HIV serostatus, so the overall smoking exposure may have been insufficient to cause respiratory symptoms or impact lung function.

A major strength of this analysis is the inclusion of a population-based, HIV-uninfected comparison group, allowing estimation of HIV-specific effects. Moreover, our methods included rigorous quality control procedures. For example, spirometry was conducted using bronchodilators in accordance with international standards, and automated quality control and interpretation algorithms were evaluated by two pulmonologists. Lastly, respiratory

symptoms were collected using a standardized questionnaire, facilitating comparison across other cohorts.

We also acknowledge several limitations. Pulmonary function was measured once per participant, thus the timing of HIV or tuberculosis infection in relation to the onset of COPD is unknown. To better assess the latter, we will be conducting repeat testing in this study population to investigate associations between HIV infection and pulmonary function trajectories. We do not have chest imaging on study participants, so we cannot exclude non-COPD etiologies of irreversible obstruction such as bronchiectasis. DLCO measurements are unavailable locally due to infrastructure limitations, thus we cannot comment on differences in interstitial or pulmonary vascular abnormalities by HIV serostatus. The measured COPD prevalence was lower than anticipated based on other studies in the region[40], so we were underpowered to identify independent correlates of COPD. Although a larger proportion of HIV-uninfected participants declined spirometry, there were no detectable differences in demographics, respiratory symptoms or smoking history between those who accepted and those who declined testing. Lastly, the study was conducted among older-aged people living in rural Uganda, so generalization to a younger or urban Ugandan population will require additional data.

Widespread availability of antiretroviral therapy, broadening inclusion criteria for therapy initiation and improved clinical care infrastructure throughout SSA have improved life expectancy for PLWH[49–51] and shifted the health priorities to include diagnosis and management of non-communicable diseases. In this study we add to the evidence base for the importance of non-communicable disease screening among PLWH by demonstrating that, in rural Uganda, COPD prevalence seems to be higher among PLWH, as well as in those with a history of tuberculosis. Future work is needed to understand the relative contributions of HIV-mediated inflammation, tuberculosis, and environmental risks such as biomass smoke, tobacco smoke and air pollution, and to better delineate the impact of lung disease on health and quality of life in this population. If our findings are confirmed, the vast investment in health care infrastructure made possible by the response to the HIV epidemic would allow an important opportunity to implement screening, diagnostic and therapeutic services for lung disease.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

We thank the Uganda Non-Communicable Diseases and Aging Cohort study participants who made this study possible by participating in this work; and Sheila Abasabyoona, Zulaika Namboga, Doreen Kyomuhendo, Alan Babweteera, and members of the HopeNet Study team for research assistance. No endorsement of manuscript contents or conclusions should be inferred from these acknowledgements.

Funding

This study was funded by the U.S. National Institutes of Health R21HL124712, P30AI060354, P30ES000002, R24AG044325, R25TW009337, and Friends of a Healthy Uganda. The authors acknowledge the following additional sources of support: T32HL116275, K23MH096620 and K23MH099916. Travel support for study investigators was provided by the travel award programs of Massachusetts General Hospital Global Health and the

Partners Center of Expertise in Global and Humanitarian Health. Biostatistical consultation was provided with support from Harvard Catalyst, the Harvard Clinical and Translational Science Center (UL1TR001102) and financial contributions from Harvard University and its affiliated academic healthcare centers. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Harvard Catalyst, Harvard University and its affiliated academic healthcare centers, or the National Institutes of Health.

References Cited

1. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 (2015). *Lancet* 385 (9963):117–171. doi: 10.1016/S0140-6736(14)61682-2 [PubMed: 25530442]
2. Diaz-Guzman E, Mannino DM (2014) Epidemiology and prevalence of chronic obstructive pulmonary disease. *Clinics in chest medicine* 35 (1):7–16. doi:10.1016/j.ccm.2013.10.002 [PubMed: 24507833]
3. Eisner MD, Anthonisen N, Coultas D et al. (2010) An official American Thoracic Society public policy statement: Novel risk factors and the global burden of chronic obstructive pulmonary disease. *American journal of respiratory and critical care medicine* 182 (5):693–718. doi:10.1164/rccm.200811-1757ST [PubMed: 20802169]
4. Respiratory diseases in the world: Realities of today - Opportunities for tomorrow. Fourm of Interntational Respiratory Societies. 2013 Available at: <https://www.ersnet.org/pdf/publications/firs-world-report.pdf>.
5. Drummond MB, Huang L, Diaz PT et al. (2015) Factors associated with abnormal spirometry among HIV-infected individuals. *AIDS* 29 (13):1691–1700. doi:10.1097/QAD.0000000000000750 [PubMed: 26372280]
6. Crothers K, Butt AA, Gibert CL et al. (2006) Increased COPD among HIV-positive compared to HIV-negative veterans. *Chest* 130 (5):1326–1333. doi:10.1378/chest.130.5.1326 [PubMed: 17099007]
7. Crothers K, Huang L, Goulet JL et al. (2011) HIV infection and risk for incident pulmonary diseases in the combination antiretroviral therapy era. *Am J Respir Crit Care Med* 183 (3):388–395. doi: 10.1164/rccm.201006-0836OC [PubMed: 20851926]
8. Drummond MB, Merlo CA, Astemborski J et al. (2013) The effect of HIV infection on longitudinal lung function decline among IDUs: a prospective cohort. *Aids* 27 (8):1303–1311. doi:10.1097/QAD.0b013e32835e395d [PubMed: 23299176]
9. George MP, Kannass M, Huang L et al. (2009) Respiratory symptoms and airway obstruction in HIV-infected subjects in the HAART era. *PLoS One* 4 (7):e6328. doi:10.1371/journal.pone.0006328 [PubMed: 19621086]
10. Drummond MB, Kirk GD, Astemborski J et al. (2012) Association between obstructive lung disease and markers of HIV infection in a high-risk cohort. *Thorax* 67 (4):309–314. doi:10.1136/thoraxjnl-2011-200702 [PubMed: 22090038]
11. Risso K, Guillouet-de-Salvador F, Valerio L et al. (2017) COPD in HIV-Infected Patients: CD4 Cell Count Highly Correlated. *PLoS One* 12 (1):e0169359. doi:10.1371/journal.pone.0169359 [PubMed: 28056048]
12. van Zyl Smit RN, Pai M, Yew WW et al. (2010) Global lung health: the colliding epidemics of tuberculosis, tobacco smoking, HIV and COPD. *Eur Respir J* 35 (1):27–33. doi: 10.1183/09031936.00072909 [PubMed: 20044459]
13. Ferris BG (1978) Epidemiology Standardization Project (American Thoracic Society). *Am Rev Respir Dis* 118 (6 Pt 2):1–120
14. Filmer D, Pritchett LH (2001) Estimating wealth effects without expenditure data—or tears: an application to educational enrollments in states of India. *Demography* 38 (1):115–132 [PubMed: 11227840]
15. WHO STEPwise approach to noncommunicable disease risk factor surveillance (STEPS). <http://www.who.int/chp/steps/riskfactor/en/>.
16. Miller MR, Hankinson J, Brusasco V et al. (2005) Standardisation of spirometry. *The European respiratory journal* 26 (2):319–338. doi:10.1183/09031936.05.00034805 [PubMed: 16055882]

17. Hankinson JL, Odencrantz JR, Fedan KB (1999) Spirometric reference values from a sample of the general U.S. population. *Am J Respir Crit Care Med* 159 (1):179–187. doi:10.1164/ajrccm.159.1.9712108 [PubMed: 9872837]
18. Musafiri S, van Meerbeeck JP, Musango L et al. (2013) Spirometric reference values for an East-African population. *Respiration; international review of thoracic diseases* 85 (4):297–304. doi: 10.1159/000337256 [PubMed: 22584423]
19. Pellegrino R, Viegi G, Brusasco V et al. (2005) Interpretative strategies for lung function tests. *Eur Respir J* 26 (5):948–968. doi:10.1183/09031936.05.00035205 [PubMed: 16264058]
20. Vestbo J, Hurd SS, Agusti AG et al. (2013) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. *Am J Respir Crit Care Med* 187 (4):347–365. doi:10.1164/rccm.201204-0596PP [PubMed: 22878278]
21. Pefura-Yone EW, Fodjeu G, Kengne AP et al. (2015) Prevalence and determinants of chronic obstructive pulmonary disease in HIV infected patients in an African country with low level of tobacco smoking. *Respir Med* 109 (2):247–254. doi:10.1016/j.rmed.2014.12.003 [PubMed: 25538018]
22. Akanbi MO, Taiwo BO, Achenbach CJ et al. (2015) HIV Associated Chronic Obstructive Pulmonary Disease in Nigeria. *J AIDS Clin Res* 6 (5). doi:10.4172/2155-6113.1000453
23. Meghji J, Nadeau G, Davis KJ et al. (2016) Noncommunicable Lung Disease in Sub-Saharan Africa. A Community-based Cross-Sectional Study of Adults in Urban Malawi. *American journal of respiratory and critical care medicine* 194 (1):67–76. doi:10.1164/rccm.201509-1807OC [PubMed: 26788760]
24. Gingo MR, Morris A, Crothers K (2013) Human immunodeficiency virus-associated obstructive lung diseases. *Clin Chest Med* 34 (2):273–282. doi:10.1016/j.ccm.2013.02.002 [PubMed: 23702176]
25. Amaral AF, Coton S, Kato B et al. (2015) Tuberculosis associates with both airflow obstruction and low lung function: BOLD results. *Eur Respir J* 46 (4):1104–1112. doi: 10.1183/13993003.02325-2014 [PubMed: 26113680]
26. Fitzpatrick ME, Singh V, Bertolet M et al. (2014) Relationships of pulmonary function, inflammation, and T-cell activation and senescence in an HIV-infected cohort. *Aids* 28 (17):2505–2515. doi:10.1097/QAD.0000000000000471 [PubMed: 25574956]
27. Fitzpatrick ME, Nouriaie M, Gingo MR et al. (2016) Novel relationships of markers of monocyte activation and endothelial dysfunction with pulmonary dysfunction in HIV-infected persons. *AIDS* 30 (9):1327–1339. doi:10.1097/QAD.0000000000001092 [PubMed: 26990629]
28. Lassiter C, Fan X, Joshi PC et al. (2009) HIV-1 transgene expression in rats causes oxidant stress and alveolar epithelial barrier dysfunction. *AIDS research and therapy* 6:1. doi: 10.1186/1742-6405-6-1 [PubMed: 19193217]
29. Neff CP, Chain JL, MaWhinney S et al. (2015) Lymphocytic alveolitis is associated with the accumulation of functionally impaired HIV-specific T cells in the lung of antiretroviral therapy-naïve subjects. *Am J Respir Crit Care Med* 191 (4):464–473. doi:10.1164/rccm.201408-1521OC [PubMed: 25536276]
30. Jia H, Lohr M, Jezequel S et al. (2001) Cysteine-rich and basic domain HIV-1 Tat peptides inhibit angiogenesis and induce endothelial cell apoptosis. *Biochemical and biophysical research communications* 283 (2):469–479. doi:10.1006/bbrc.2001.4790 [PubMed: 11327725]
31. Morris A, Alexander T, Radhi S et al. (2009) Airway obstruction is increased in pneumocystis-colonized human immunodeficiency virus-infected outpatients. *J Clin Microbiol* 47 (11):3773–3776. doi:10.1128/JCM.01712-09 [PubMed: 19759224]
32. Kristoffersen US, Lebech AM, Mortensen J et al. (2012) Changes in lung function of HIV-infected patients: a 4.5-year follow-up study. *Clin Physiol Funct Imaging* 32 (4):288–295. doi:10.1111/j.1475-097X.2012.01124.x [PubMed: 22681606]
33. Gingo MR, George MP, Kessinger CJ et al. (2010) Pulmonary function abnormalities in HIV-infected patients during the current antiretroviral therapy era. *Am J Respir Crit Care Med* 182 (6): 790–796. doi:10.1164/rccm.200912-1858OC [PubMed: 20522793]
34. Kunisaki KM, Niewoehner DE, Collins G et al. (2016) Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the

- multicentre, international, randomised, controlled Strategic Timing of Antiretroviral Treatment (START) trial. *Lancet Respir Med* 4 (12):980–989. doi:10.1016/S2213-2600(16)30319-8 [PubMed: 27773665]
35. Siedner MJ, Ng CK, Bassett IV et al. (2015) Trends in CD4 count at presentation to care and treatment initiation in sub-Saharan Africa, 2002–2013: a meta-analysis. *Clin Infect Dis* 60 (7): 1120–1127. doi:10.1093/cid/ciu1137 [PubMed: 25516189]
 36. Boum Y, 2nd, Atwine D, Orikiriza P et al. (2014) Male Gender is independently associated with pulmonary tuberculosis among sputum and non-sputum producers people with presumptive tuberculosis in Southwestern Uganda. *BMC Infect Dis* 14:638. doi:10.1186/s12879-014-0638-5 [PubMed: 25492725]
 37. Borgdorff MW, Nagelkerke NJ, Dye C et al. (2000) Gender and tuberculosis: a comparison of prevalence surveys with notification data to explore sex differences in case detection. *Int J Tuberc Lung Dis* 4 (2):123–132 [PubMed: 10694090]
 38. Hamid Salim MA, Declercq E, Van Deun A et al. (2004) Gender differences in tuberculosis: a prevalence survey done in Bangladesh. *Int J Tuberc Lung Dis* 8 (8):952–957 [PubMed: 15305476]
 39. Neyrolles O, Quintana-Murci L (2009) Sexual inequality in tuberculosis. *PLoS Med* 6 (12):e1000199. doi:10.1371/journal.pmed.1000199 [PubMed: 20027210]
 40. van Gemert F, Kirenga B, Chavannes N et al. (2015) Prevalence of chronic obstructive pulmonary disease and associated risk factors in Uganda (FRESH AIR Uganda): a prospective cross-sectional observational study. *Lancet Glob Health* 3 (1):e44–51. doi:10.1016/S2214-109X(14)70337-7 [PubMed: 25539969]
 41. Buist AS, McBurnie MA, Vollmer WM et al. (2007) International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. *Lancet* 370 (9589):741–750. doi: 10.1016/S0140-6736(07)61377-4 [PubMed: 17765523]
 42. Adeloye D, Basquill C, Papan A et al. (2015) An estimate of the prevalence of COPD in Africa: a systematic analysis. *COPD* 12 (1):71–81. doi:10.3109/15412555.2014.908834 [PubMed: 24946179]
 43. Pinkerton KE, Harbaugh M, Han MK et al. (2015) Women and Lung Disease. Sex Differences and Global Health Disparities. *Am J Respir Crit Care Med* 192 (1):11–16. doi:10.1164/rccm.201409-1740PP [PubMed: 25945507]
 44. Hardin M, Cho MH, Sharma S et al. (2017) Sex-Based Genetic Association Study Identifies CELSR1 as a Possible Chronic Obstructive Pulmonary Disease Risk Locus among Women. *Am J Respir Cell Mol Biol* 56 (3):332–341. doi:10.1165/rcmb.2016-0172OC [PubMed: 27854507]
 45. Wan ES, Qiu W, Carey VJ et al. (2015) Smoking-Associated Site-Specific Differential Methylation in Buccal Mucosa in the COPD Gene Study. *Am J Respir Cell Mol Biol* 53 (2):246–254. doi: 10.1165/rcmb.2014-0103OC [PubMed: 25517428]
 46. Amaral AFS, Strachan DP, Burney PGJ et al. (2017) Female Smokers Are at Greater Risk of Airflow Obstruction Than Male Smokers UK Biobank. *Am J Respir Crit Care Med* 195 (9):1226–1235. doi:10.1164/rccm.201608-1545OC [PubMed: 28075609]
 47. Kruse GR, Bangsberg DR, Hahn JA et al. (2014) Tobacco use among adults initiating treatment for HIV infection in rural Uganda. *AIDS and behavior* 18 (7):1381–1389. doi:10.1007/s10461-014-0737-8 [PubMed: 24638166]
 48. Pampel F (2008) Tobacco use in sub-Saharan Africa: estimates from the demographic health surveys. *Soc Sci Med* 66 (8):1772–1783. doi:10.1016/j.socscimed.2007.12.003 [PubMed: 18249479]
 49. Mills EJ, Bakanda C, Birungi J et al. (2011) Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. *Ann Intern Med* 155 (4):209–216. doi:10.7326/0003-4819-155-4-201108160-00358 [PubMed: 21768555]
 50. Nsanzimana S, Remera E, Kanters S et al. (2015) Life expectancy among HIV-positive patients in Rwanda: a retrospective observational cohort study. *Lancet Glob Health* 3 (3):e169–177. doi: 10.1016/S2214-109X(14)70364-X [PubMed: 25701995]
 51. Bor J, Herbst AJ, Newell ML et al. (2013) Increases in adult life expectancy in rural South Africa: valuing the scale-up of HIV treatment. *Science* 339 (6122):961–965. doi:10.1126/science.1230413 [PubMed: 23430655]




Figure 1:
Self-reported respiratory symptoms

Table 1:Baseline Characteristics, including those with and without ATS acceptable spirometry, *n(%) or median[IQR]*

Characteristic	Total Cohort (n = 269)	HIV + (n = 143)	HIV – (n = 126)	<i>p value</i>
Age, years	52 [48, 55]	52 [49, 56]	52 [48, 55]	<i>NS</i>
Women	125 (46)	66 (46)	59 (47)	<i>NS</i>
Body Mass Index (kg/m²)				<i>0.02</i>
Underweight (< 18.5)	31 (12)	9 (6)	22 (17)	
Normal (18.5 – 25)	153 (57)	89 (62)	64 (51)	
Overweight (25.1 – 30)	52 (19)	30 (21)	22 (17)	
Obese (> 30)	33 (12)	15 (10)	18 (14)	
Smoking History				<i>0.01</i>
Never	139 (52)	82 (57)	57 (45)	
Former	89 (33)	48 (34)	41 (33)	
Current	41 (15)	13 (9)	28 (22)	
Years Smoked *	18 [10, 32]	17 [10, 26]	24 [11, 35]	<i>NS</i>
Pack-Years *	4 [1, 7]	3 [1, 8]	4 [1, 7]	<i>NS</i>
Farmer	179 (67)	76 (53)	103 (82)	<i><0.001</i>
Medical History †				
COPD	4 (1)	3 (2)	1 (1)	<i>NS</i>
Asthma	5 (2)	4 (3)	1 (1)	<i>NS</i>
Pneumonia	23 (9)	18 (13)	5 (4)	<i>0.01</i>
Tuberculosis	18 (7)	18 (13)	0 (0)	<i><0.001</i>
Biomass Exposure				<i><0.001</i>
Charcoal	38 (14)	37 (26)	1 (1)	
Firewood	229 (86)	104 (74)	125 (99)	
Education				<i>0.06</i>
Did not complete primary school	148 (55)	69 (48)	79 (63)	
Completed primary school	91 (34)	55 (38)	36 (29)	
Completed secondary school	30 (11)	19 (13)	11 (9)	
Asset Ownership Index ‡				<i><0.001</i>
Poorest	61 (23)	28 (20)	33 (26)	
Poorer	71 (26)	27 (19)	44 (35)	
Richer	65 (24)	34 (24)	31 (25)	
Richest	71 (26)	54 (38)	17 (14)	

* Current or former smokers only

† Self-reported history

‡ Filmer and Pritchett (18)

Table 2:

HIV-related clinical characteristics (n = 143), n (%)

	Total Cohort (n = 143)	COPD (n=8)	No COPD (n=135)	P value
CD4 cell count, current (cells/m ³)				NS
< 100	0 (0)	0 (0)	0 (0)	
100 – 349	26 (18)	3 (38)	23 (17)	
350 – 499	54 (38)	2 (25)	52 (39)	
500	63 (44)	3 (38)	60 (44)	
CD4 cell count, nadir [*] (cells/m ³)				NS
< 100	50 (35)	3 (38)	47 (35)	
100 – 349	90 (63)	5 (63)	85 (63)	
350 – 499	2 (1)	0 (0)	2 (1)	
500	1 (1)	0 (0)	1 (1)	
Viral Load , copies/μL				NS
Undetectable	131 (92)	8 (100)	123 (91)	
Detectable, < 10,000	6 (4)	0 (0)	6 (4)	
10,000	1 (1)	0 (0)	1 (1)	
Years on antiretroviral therapy	9 [8, 10]	8 [8, 10]	9 [8, 10]	NS
Current antiretroviral regimen [†]				NS
AZT/3TC/NVP or EFV	112 (78)	6 (75)	106 (79)	
TDF/3TC/NVP or EFV	18 (13)	1 (13)	17 (13)	
TDF/3TC/LPV/r	12 (8)	1 (13)	11 (8)	
AZT/3TC/ABC	1 (1)	0 (0)	1 (1)	

* Measured prior to antiretroviral therapy initiation

[†] AZT, zidovudine; 3TC, lamivudine; NVP, nevirapine; TDF, tenofovir; EFV, efavirenz; LPV/r, lopinavir/ritonavir, ABC, abacavir

Table 3.

Predictors of decreased FEV1 (percent predicted) and respiratory symptoms

	FEV1 (% predicted), n = 239			Respiratory Symptoms, n = 287		
	Unadjusted		Adjusted	Unadjusted		Adjusted
	Estimate	95% CI	Estimate	OR	95% CI	AOR
Age, per year	0.5**	0.2, 0.9	0.5**	1.03	0.99, 1.07	1.04
Female	0.1	-4.5, 4.6		4.09***	2.28, 7.34	3.88***
Ever Smoker	0.5	-4.1, 5.0	0.3	1.05	0.61, 1.79	1.74
Asset Index						
Poorer	-3.5	-9.9, 2.8		0.65	0.31, 1.35	0.61
Richer	-2.9	-9.4, 3.6		0.37*	0.16, 0.85	0.31*
Richest	-4.6	-11.0, 1.8		0.77	0.38, 1.59	0.44
BMI						
< 18.5	-5.2	-12.7, 2.3		0.77	0.30, 2.01	0.74
25	-2.2	-7.2, 2.8		1.81*	1.01, 3.22	1.36
HIV	-3.2	-7.7, 1.3	-1.8	1.42	0.83, 2.44	
TB	-16.1***	-24.9, -7.2	-14.4**	1.86	0.70, 4.92	
Biomass (Charcoal)	1.9	-4.7, 8.5		2.68**	1.33, 5.37	3.17*
Farmer	1.8	-3.0, 6.6		1.04	0.59, 1.85	
HIV Characteristics, n=143						
CD4 Count						
350 – 499	3.7	-3.4 – 10.8	5.4		-1.7 – 12.5	
< 350	-10.6*	-19.5 – -1.7	-9.0*		-17.8 – -0.1	
Viral Load 10,000 copies	-25.9**	-40.9 – -10.8	-26.7***		-41.4 – -12.0	
ART duration, per year	-0.3	-2.1 – 1.5	-0.7		-2.5 – 1.1	
ART regimen (AZT-based)	1.9	-6.5 – 10.3	1.7		-6.8 – 10.2	

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Reference categories - BMI: 18.5 – 24.9; Asset index: Poorest; CD4 count: >500 cells; viral load: < 10,000 copies; ART regimen: non-AZT based therapy

% predicted based on NHANESIII prediction equations (Ref 15 in text)

* $p < 0.05$,

** $p < 0.01$,

*** $p < 0.001$

Table 4:

Differences in COPD prevalence by covariates of interest

	COPD (n=9)	No COPD (n=230)	P value
HIV Positive	8 (89)	135 (52)	0.04
Age			NS
< 50 years	2 (22)	91 (35)	
50 - 53 years	5 (56)	83 (32)	
54 years	2 (22)	86 (33)	
Male gender	9 (100)	135 (52)	<0.01
Prior Tuberculosis	6 (67)	12 (5)	<0.001
BMI (kg/m ³)			NS
< 18.5	2 (22)	29 (11)	
18.5 – 24.9	6 (67)	147 (57)	
25	1 (11)	84 (32)	
Ever-Smoker	7 (78)	123 (47)	NS
Asset Ownership Index			NS
Poorest	2 (22)	59 (23)	
Poorer	2 (22)	69 (27)	
Richer	1 (11)	64 (25)	
Richest	4 (44)	67 (26)	
Education			NS
Did not complete primary school	5 (56)	143 (55)	
Completed primary school	4 (44)	87 (33)	
Completed at least some secondary school	0 (0)	30 (12)	
Farmer	6 (67)	173 (66)	NS
CD4 count			NS
< 350	3 (38)	60 (44)	
350 – 499	2 (25)	52 (39)	
500	3 (38)	23 (17)	
Undetectable Viral Load	8 (100)	123 (95)	NS
ART duration			NS
< 8 years	1 (14)	32 (24)	
8 - 9.9 years	5 (71)	72 (54)	